Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical ...

Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicines despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trail. | Analysts are keeping ...

Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. | ...

Scientists have identified a new class of compounds capable of partially clearing the tropical parasite that causes Chagas ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

Medtronic reported that it has begun testing an expansion of its renal denervation approach for dropping stubbornly high ...

Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the ...

Mendaera has claimed an FDA clearance for its handheld robotic needle delivery system, for precision placement guided by ...

Jasper Therapeutics’ dud drug lot has cost half of the biotech's employees their jobs. | Jasper Therapeutics’ dud drug lot ...

Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | ...

At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...